220 related articles for article (PubMed ID: 26083990)
21. Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism.
Nylander S; Femia EA; Scavone M; Berntsson P; Asztély AK; Nelander K; Löfgren L; Nilsson RG; Cattaneo M
J Thromb Haemost; 2013 Oct; 11(10):1867-76. PubMed ID: 23890048
[TBL] [Abstract][Full Text] [Related]
22. Platelet reactivity after administration of third generation P2Y12-antagonists does not depend on body weight in contrast to clopidogrel.
Olivier CB; Schnabel K; Weber S; Zhou Q; Bode C; Moser M; Diehl P
J Thromb Thrombolysis; 2016 Jul; 42(1):84-9. PubMed ID: 26837379
[TBL] [Abstract][Full Text] [Related]
23. Pharmacodynamic Effects of Ticagrelor Dosing Regimens in Patients on Maintenance Ticagrelor Therapy: Results From a Prospective, Randomized, Double-Blind Investigation.
Cho JR; Rollini F; Franchi F; DeGroat C; Bhatti M; Dunn EC; Ferrante E; Muniz-Lozano A; Suryadevara S; Zenni MM; Guzman LA; Bass TA; Angiolillo DJ
JACC Cardiovasc Interv; 2015 Jul; 8(8):1075-1083. PubMed ID: 26117466
[TBL] [Abstract][Full Text] [Related]
24. The GNB3 C825T polymorphism influences platelet aggregation in human whole blood.
Dusse F; Frey UH; Bilalic A; Dirkmann D; Görlinger K; Siffert W; Peters J
Pharmacogenet Genomics; 2012 Jan; 22(1):43-9. PubMed ID: 22082654
[TBL] [Abstract][Full Text] [Related]
25. Exploration of efficacy and bleeding with combined phosphoinositide 3-kinase β inhibition and aspirin in man.
Nylander S; Wågberg F; Andersson M; Skärby T; Gustafsson D
J Thromb Haemost; 2015 Aug; 13(8):1494-502. PubMed ID: 26096765
[TBL] [Abstract][Full Text] [Related]
26. Signaling via P2Y12 may be critical for early stabilization of platelet aggregates.
Speich HE; Bhal V; Houser KH; Caughran AT; Lands LT; Houng AK; Bäckstrom J; Enerbäck M; Reed GL; Jennings LK
J Cardiovasc Pharmacol; 2014 Jun; 63(6):520-7. PubMed ID: 24477045
[TBL] [Abstract][Full Text] [Related]
27. SAR216471, an alternative to the use of currently available P2Y₁₂ receptor inhibitors?
Delesque-Touchard N; Pflieger AM; Bonnet-Lignon S; Millet L; Salel V; Boldron C; Lassalle G; Herbert JM; Savi P; Bono F
Thromb Res; 2014 Sep; 134(3):693-703. PubMed ID: 25064036
[TBL] [Abstract][Full Text] [Related]
28. Pharmacodynamic interplay of the P2Y(1), P2Y(12), and TxA(2) pathways in platelets: the potential of triple antiplatelet therapy with P2Y(1) receptor antagonism.
Oestreich JH; Ferraris SP; Steinhubl SR; Akers WS
Thromb Res; 2013 Feb; 131(2):e64-70. PubMed ID: 23245937
[TBL] [Abstract][Full Text] [Related]
29. P2Y12 polymorphisms and antiplatelet effects of aspirin in patients with coronary artery disease.
Bierend A; Rau T; Maas R; Schwedhelm E; Böger RH
Br J Clin Pharmacol; 2008 Apr; 65(4):540-7. PubMed ID: 17995973
[TBL] [Abstract][Full Text] [Related]
30. Pharmacodynamic effects during the transition between cangrelor and ticagrelor.
Schneider DJ; Agarwal Z; Seecheran N; Keating FK; Gogo P
JACC Cardiovasc Interv; 2014 Apr; 7(4):435-42. PubMed ID: 24656538
[TBL] [Abstract][Full Text] [Related]
31. Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation.
VAN Giezen JJ; Nilsson L; Berntsson P; Wissing BM; Giordanetto F; Tomlinson W; Greasley PJ
J Thromb Haemost; 2009 Sep; 7(9):1556-65. PubMed ID: 19552634
[TBL] [Abstract][Full Text] [Related]
32. The influence of variation in the P2Y12 receptor gene on in vitro platelet inhibition with the direct P2Y12 antagonist cangrelor.
Bouman HJ; van Werkum JW; Rudez G; Leebeek FW; Kruit A; Hackeng CM; Ten Berg JM; de Maat MP; Ruven HJ
Thromb Haemost; 2010 Feb; 103(2):379-86. PubMed ID: 20126830
[TBL] [Abstract][Full Text] [Related]
33. Impact of ticagrelor on P2Y1 and P2Y12 localization and on cholesterol levels in platelet plasma membrane.
Rabani V; Montange D; Meneveau N; Davani S
Platelets; 2018 Nov; 29(7):709-715. PubMed ID: 29020490
[TBL] [Abstract][Full Text] [Related]
34. Genotyping-guided approach versus the conventional approach in selection of oral P2Y12 receptor blockers in Chinese patients suffering from acute coronary syndrome.
Tam CC; Kwok J; Wong A; Yung A; Shea C; Kong SL; Tang WH; Siu D; Chan R; Lee S
J Int Med Res; 2017 Feb; 45(1):134-146. PubMed ID: 28222641
[TBL] [Abstract][Full Text] [Related]
35. Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes status.
Thomas MR; Angiolillo DJ; Bonaca MP; Ajjan RA; Judge HM; Rollini F; Franchi F; Ahsan AJ; Bhatt DL; Kuder JF; Steg PG; Cohen M; Muthusamy R; Sabatine MS; Storey RF
Thromb Haemost; 2017 May; 117(5):940-947. PubMed ID: 28300867
[TBL] [Abstract][Full Text] [Related]
36. The role of adenosine diphosphate mediated platelet responsiveness for the stability of platelet integrity in citrated whole blood under ex vivo conditions.
Koessler J; Schwarz M; Weber K; Etzel J; Koessler A; Boeck M; Kobsar A
PLoS One; 2017; 12(11):e0188193. PubMed ID: 29155852
[TBL] [Abstract][Full Text] [Related]
37. A pharmacodynamic study of the optimal P2Y12 inhibitor regimen for East Asian patients with acute coronary syndrome.
Lee JH; Ahn SG; Park B; Park SW; Kang YS; Lee JW; Youn YJ; Ahn MS; Kim JY; Yoo BS; Lee SH; Yoon J
Korean J Intern Med; 2015 Sep; 30(5):620-8. PubMed ID: 26354056
[TBL] [Abstract][Full Text] [Related]
38. Inverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor.
Aungraheeta R; Conibear A; Butler M; Kelly E; Nylander S; Mumford A; Mundell SJ
Blood; 2016 Dec; 128(23):2717-2728. PubMed ID: 27694321
[TBL] [Abstract][Full Text] [Related]
39. Selective serotonin reuptake inhibitors reduce P2Y12 receptor-mediated amplification of platelet aggregation.
Tseng YL; Chiang ML; Lane HY; Su KP; Lai YC
Thromb Res; 2013 Apr; 131(4):325-32. PubMed ID: 23490430
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y(12) antagonists in an ex-vivo canine model.
Ravnefjord A; Weilitz J; Emanuelsson BM; van Giezen JJ
Thromb Res; 2012 Oct; 130(4):622-8. PubMed ID: 22909827
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
